Our GMP, Your IND

Advancing Vaccines and BioTherapeutics

Solutions Through Immunology

Advancing Vaccines and BioTherapeutics

Breakthroughs Delivered

Advancing Vaccines and BioTherapeutics

About ABL

ABL provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market.

Learn More
Spotlight

ABL Europe Enters into a Collaboration for the GMP Manufacture of Hookipa Biotech’s Heterologous Viral Vector Immunotherapy Platform

Hookipa Biotech AG, a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology, and ABL Europe SAS, an ABL Inc. company providing dedicated viral vector GMP contract manufacturing (CMO) services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch, have entered in a manufacturing collaboration.

Read More

Najít Technologies Partners with ABL for Development of Novel Vaccine Platform

ABL is working with Najít Technologies, Inc. to advance the development of Najít’s novel HydroVax™ vaccine platform. ABL will utilize its GMP manufacturing expertise for the advanced development of virus-based vaccine candidates to protect against a number of emerging and re-emerging infectious diseases.

Read More

Aushon BioSystems and ABL, Inc. Announce Adoption of the Cira™ Platform for Multiplex and Ultrasensitive Biomarker Testing

ABL strengthens biomarker capabilities for a wide range of disease states with the Cira platform.

Read More

ABL, Inc. Earned GCLP Certificate of Accreditation

In Q1 2017, ABL was awarded a certificate of full accreditation after satisfactorily implementing the requirements set out in the Good Clinical Laboratory Practice (GCLP), an international standard developed by the World Health Organization (WHO) to close the gap between preclinical GLP and GCP testing.

Learn More